Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Nov;127(8):1479-1486.
doi: 10.1038/s41416-022-01897-1. Epub 2022 Jul 22.

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

Lucia Musacchio  1 , Daniela Califano  2 , Michele Bartoletti  3   4 , Laura Arenare  5 , Domenica Lorusso  1   6 , Nunzia Simona Losito  7 , Gennaro Cormio  8   9 , Stefano Greggi  10 , Francesco Raspagliesi  11 , Giorgio Valabrega  12 , Vanda Salutari  1 , Carmela Pisano  13 , Anna Spina  2 , Daniela Russo  2 , Michele Del Sesto  7 , Vincenzo Canzonieri  14   15 , Francesco Ferraù  16 , Gian Franco Zannoni  17   18 , Vera Loizzi  9 , Viola Ghizzoni  1 , Claudia Casanova  19 , Valentina Tuninetti  12 , Monika Ducceschi  11 , Vittoria Del Vecchio  9 , Simona Scalone  4 , Domenico Priolo  16 , Francesco Perrone  5 , Giovanni Scambia  1   6 , Sandro Pignata  20
Affiliations
Observational Study

Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22)

Lucia Musacchio et al. Br J Cancer. 2022 Nov.

Abstract

Background: Low-grade serous ovarian and peritoneal cancer (LGSC) is a rare disease and few data on the clinical and genomic landscape have been published.

Methods: A retrospective analysis of patients diagnosed with LGSC between 1996 and 2019 was conducted in MITO centers. Objective Response Rate (ORR) to treatments, progression-free survival (PFS) and overall survival (OS) were assessed. Additionally, the tumor molecular profile of 56 patients was evaluated using the Next Generation Sequencing (NGS) FoundationOne CDX (Foundation Medicine®).

Results: A total of 128 patients with complete clinical data and pathologically confirmed diagnosis of LGSC were identified. ORR to first and subsequent therapies were 23.7% and 33.7%, respectively. PFS was 43.9 months (95% CI:32.4-53.1) and OS was 105.4 months (95% CI: 82.7-not reached). The most common gene alterations were: KRAS (n = 12, 21%), CDKN2A/B (n = 11, 20%), NRAS (n = 8, 14%), FANCA (n = 8, 14%), NF1 (n = 7, 13%) and BRAF (n = 6, 11%). Unexpectedly, pathogenetic BRCA1 (n = 2, 4%), BRCA2 (n = 1, 2%) and PALB2 (n = 1, 2%) mutations were found.

Conclusions: MITO 22 suggests that LGSC is an heterogenous disease for both its clinical behavior in response to standard therapies and its molecular alterations. Future prospective studies should test treatments according to biological and molecular tumor's characteristics.

Clinical trial registration: This study is registered under NCT02408536 on ClinicalTrials.gov .

PubMed Disclaimer

Conflict of interest statement

DL reports research funding from Clovis, GSK and MSD, personal interests with AstraZeneca, Clovis Oncology, GSK, Pharmamar, MSD and financial interests with Clovis, Genmab, GSK, MSD. Board of Directors, GCIG (Gynecologic Cancer Inter Group). FR reports honoraria from GSK, Pharmamar, Clovis, MSD and Roche. VS reports honoraria from GSK, PharmaMar, Roche, MSD, EISAI, Clovis, Oncology, AstraZeneca. FP reports honoraria for educational and advisory activity from Incyte, GSK, Eli Lilly, Ipsen, Astellas, AstraZeneca, Roche, BMS, Bayer, Clovis, Pierre Fabre and grants for clinical trials to his institution from Roche, Astra Zeneca, Pfizer, MSD, Bayer, Incyte Taiho, Janssen, Exelixis, Ailenor, Daiichi Sankyo. GS reports research support from MSD and honoraria from Clovis Oncology. Consultant for Tesaro and Johnson & Johnson. SP reports honoraria from AstraZeneca, MSD, Roche, Pfizer, Clovis, GSK, Pharmamar and research funding from MSD, Roche, Astrazeneca and Pfizer. LM, DC, MB, LA, NSL, GC, SG, GV, CP, AS, DR, MDS, VC, FF, GFZ, VL, VG, CC, VT, MD, VDV, SS and DP have nothing to disclose.

Figures

Fig. 1
Fig. 1. Progression-Free Survival (PFS) of the overall population.
The median PFS was 43.9 months (95% CI: 32.4–53.1).
Fig. 2
Fig. 2. Overall Survival (OS) of the overall population.
The median OS was 105.4 months (95% CI: 82.7– not reached).
See this image and copyright information in PMC

References

    1. Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, et al. Low-grade serous ovarian cancer: state of the science. Gynecol Oncol. 2020;156:715–25. doi: 10.1016/j.ygyno.2019.12.033. - DOI - PubMed
    1. Gockley A, Melamed A, Bregar AJ, Clemmer JT, Birrer M, Schorge JO, et al. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol. 2017;129:439–47. doi: 10.1097/AOG.0000000000001867. - DOI - PMC - PubMed
    1. Grabowski JP, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol. 2016;140:457–62. doi: 10.1016/j.ygyno.2016.01.022. - DOI - PubMed
    1. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009;114:48–52. doi: 10.1016/j.ygyno.2009.03.001. - DOI - PubMed
    1. Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, et al. MILO/ENGOT-ov11: binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J Clin Oncol. 2020;38:3753–62. doi: 10.1200/JCO.20.01164. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources